IntraBio is a late-stage biopharmaceutical company developing novel therapies for rare (“orphan”) and common neurodegenerative diseases

Oxford, England
Joined November 2018
IntraBio Reports Positive Data from IB1001 Multinational Clinical Trial for the Treatment of GM2 Gangliosidosis (Tay-Sachs and Sandhoff disease) accesswire.com/660477/IntraB…
IntraBio Appoints Jim Meyers as President and CEO accesswire.com/618176/IntraB…
1
Professor Michael Strupp Receives the 2020 Galenus-von-Pergamon Award accesswire.com/viewarticle.a…
IntraBio Reports Further Detail on Positive Data from IB1001 Multinational Clinical Trial for the Treatment of Niemann-Pick disease Type C accesswire.com/viewarticle.a…
New hope for Treatment Against Niemann-Pick disease Type C businessnewstribune.com/2020… via @Business News Tribune
"IntraBio Reports Positive Data from NPC Study" - @GlobalGenes globalgenes.org/2020/10/06/i…
IntraBio Reports Positive Data from IB1001 Multinational Clinical Trial for the Treatment of Niemann-Pick disease Type C accesswire.com/viewarticle.a…
1
IntraBio retweeted
JOIN US THIS MORNING for the NNPDF Industry webinar series as @IntraBio presents at 11:00 am ET/8:00 am PT. Hear updates regarding their Clinical Trial IB1001-201 and more! REGISTER NOW at: bit.ly/2KYdOvD #NPC #niemannpick #nnpdf
1
2
IntraBio Investigational New Drug Application Approved by the FDA for the Treatment of Ataxia-Telangiectasia #RareDisease #IntraBio #Ataxia #FDA #Biotech accesswire.com/538752/IntraB…
1
1
3
IntraBio Clinical Trial Authorisation Application Approved by the MHRA for the treatment of Niemann-Pick Disease Type C #RareDisease #IntraBio #MHRA #NPC accesswire.com/538583/IntraB…
1
2
IntraBio Investigational New Drug Application Approved by the FDA for the Treatment of Niemann-Pick Disease Type C #RareDisease #Biotech #FDA #IntraBio #IND accesswire.com/535211/IntraB…
IntraBio Investigational New Drug Application Approved by the FDA for the Treatment of Tay-Sachs and Sandhoff Disease #RareDisease #Biotech #FDA #IntraBio accesswire.com/534958/IntraB…
1
1
IntraBio Receives Niemann-Pick Disease European Orphan Drug Designation for IB4000 #RareDisease #Biotech #IntraBio accesswire.com/532110/IntraB…
IntraBio Receives Niemann-Pick Disease Orphan Drug Designation from the FDA for IB4000 #RareDisease #FDA #Biotech #IntraBio accesswire.com/530834/IntraB…
IntraBio Receives Tay-Sachs and Sandhoff Rare Pediatric Disease Designation from the FDA #RareDisease #Biotech #IntraBio accesswire.com/530328/IntraB…
1
1
RareDaily reports on our recent Rare Pediatric Disease Designation for Niemann-Pick disease Type C for our lead compound series globalgenes.org/raredaily/fd… via @GlobalGenes
2
IntraBio Receives Spinocerebellar Ataxia Orphan Drug Designation from the FDA #IntraBio #Ataxia #RareDisease #Biotech accesswire.com/530119/IntraB…
1
IntraBio is pleased to announce that its lead drug series IB1000s has been granted Orphan Medicinal Drug Designation by the European Commission for the treatment of Spinocerebellar Ataxia #RareDisease #Ataxia #IntraBio accesswire.com/529750/IntraB…
IntraBio Receives Niemann-Pick Disease Rare Pediatric Disease Designation from the FDA for IB1000 Series #RareDisease #OrphanDisease #Biotech #NiemannPick #FDA #IntraBio accesswire.com/529563/IntraB…